ASH: Roche offers glimpse of Columvi-Polivy combo's early lymphoma data as phase 3 kicks off
Fierce Pharma
DECEMBER 10, 2023
Roche’s blood cancer portfolio is booming with new life thanks to the antibody-drug conjugate Polivy and bispecifics. | As Roche’s blood cancer portfolio booms with new life thanks to the antibody-drug conjugate Polivy and bispecifics, the company is offering a look at data for two combinations of those drugs that support two phase 3 trials in diffuse large B-cell lymphoma.
Let's personalize your content